Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER4 | P35408 | 16/20 | 0.47 |
| ▸ | PTGER2 | P43116 | 16/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4087358 | 0.87 | PTGER4 (0.55) | PTGER4PTGER2MEN1KMT2A | |
| SCHEMBL1057599 | 0.86 | PTGER4 (0.47) | PTGER4PTGER2MEN1ALDH1A1KMT2A | |
| SCHEMBL15163146 | 0.85 | PTGER4 (0.46) | PTGER4PTGER2SIGMAR1 | |
| SCHEMBL4090483 | 0.84 | PTGER2 (0.67) | PTGER4PTGER2LMNA | |
| SCHEMBL4087365 | 0.82 | PTGER4 (0.49) | PTGER4PTGER2MEN1KMT2A | |
| SCHEMBL4082485 | 0.80 | PTGER2 (0.48) | PTGER4PTGER2ALDH1A1 | |
| SCHEMBL4085409 | 0.78 | PTGER4 (0.43) | PTGER4PTGER2LMNAMEN1ALDH1A1 | |
| SCHEMBL4597894 | 0.78 | PTGER2 (0.58) | PTGER4PTGER2 | |
| SCHEMBL4087582 | 0.77 | PTGER2 (0.74) | PTGER4PTGER2 | |
| SCHEMBL4082516 | 0.77 | PTGER2 (0.44) | PTGER4PTGER2LMNAMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1847533-B1 | SIX-MEMBERED HETEROCYCLIC COMPOUND AND THE USE THEREOF | ASAHI KASEI PHARMA CORP (JP) | 2013-08-14 | — | — | EP | disclosed |
| US-7531533-B2 | 6-Membered heterocyclic compound and use thereof | ASAHI KASEI PHARMA CORPORATION (JP) | 2009-05-12 | — | — | US | disclosed |
| EP-1847533-A1 | SIX-MEMBERED HETEROCYCLIC COMPOUND AND THE USE THEREOF | Asahi Kasei Pharma Corporation (JP) | 2007-10-24 | — | — | EP | disclosed |
| US-20070060590-A1 | 6-Membered heterocyclic compound and use thereof | ASAHI KASEI PHARMA CORPORATION (JP) | 2007-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070060590-A1 | 6-Membered heterocyclic compound and use thereof | WNT1, CYP11B2, CYP11B1 | PTGER4 33/4885PTGER2 39/4885LMNA 1846/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.